Detalhe da pesquisa
1.
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
Am J Hematol;
99(5): 1001-1004, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38404143
2.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol;
200(2): 175-186, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36214090
3.
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis.
Int J Mol Sci;
24(20)2023 Oct 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37895120
4.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica;
107(12): 2859-2869, 2022 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35615931
5.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol;
194(2): 393-402, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34195988
6.
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cancer;
126(15): 3438-3447, 2020 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32459375
7.
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Br J Haematol;
186(1): 54-59, 2019 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30864168
8.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Cancer;
123(10): 1791-1799, 2017 05 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28026860
9.
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cancer;
127(6): 976-978, 2021 03 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33095912
10.
Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples.
Eur J Immunol;
45(7): 1926-33, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25903796
11.
The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.
Haematologica;
104(6): 1096-1098, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31152086
12.
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)]. / Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques).
Bull Cancer;
111(1): 87-96, 2024 Jan.
Artigo
em Francês
| MEDLINE
| ID: mdl-38087729
13.
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.
Expert Rev Hematol;
16(9): 633-639, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37427999
14.
Germline JAK2 E846D Substitution as the Cause of Erythrocytosis?
Genes (Basel);
14(5)2023 05 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37239426
15.
Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs).
Cells;
12(4)2023 02 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36831265
16.
ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia
Turk J Haematol;
40(2): 101-117, 2023 05 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37026766
17.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Leuk Res;
130: 107308, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37230027
18.
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Pharmaceutics;
14(8)2022 Aug 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36015302
19.
Innate T-αß lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinib.
Sci Rep;
10(1): 3245, 2020 02 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32094501
20.
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.
Blood Adv;
4(19): 4887-4897, 2020 10 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33035330